Renaissance Group LLC Buys New Position in Halozyme Therapeutics, Inc. $HALO

Renaissance Group LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 478,735 shares of the biopharmaceutical company’s stock, valued at approximately $35,110,000. Halozyme Therapeutics comprises approximately 1.3% of Renaissance Group LLC’s investment portfolio, making the stock its 29th biggest position.

Several other institutional investors have also recently made changes to their positions in the stock. Campbell Newman Asset Management Inc. grew its stake in shares of Halozyme Therapeutics by 0.4% in the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock valued at $2,705,000 after buying an additional 153 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the last quarter. Richardson Financial Services Inc. grew its position in shares of Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 198 shares during the period. Brown Advisory Inc. increased its holdings in shares of Halozyme Therapeutics by 0.6% during the 2nd quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock worth $1,824,000 after acquiring an additional 224 shares during the last quarter. Finally, Global Retirement Partners LLC grew its stake in Halozyme Therapeutics by 21.6% in the 3rd quarter. Global Retirement Partners LLC now owns 1,413 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 251 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on HALO shares. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday. The Goldman Sachs Group reaffirmed a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $78.80.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $81.23 on Friday. The stock has a market cap of $9.55 billion, a price-to-earnings ratio of 17.10, a PEG ratio of 0.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. Halozyme Therapeutics, Inc. has a fifty-two week low of $47.50 and a fifty-two week high of $81.36. The firm’s 50-day simple moving average is $69.43 and its 200 day simple moving average is $69.08.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Company raised 2025 and 2026 revenue guidance, prompting fresh valuation attention and supporting higher expectations for revenue growth going forward. This is a primary driver of the intraday uptick. A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance
• Positive Sentiment: Analysts have been revising near-term earnings and EPS forecasts upward (including a raised Q1 EPS estimate), which supports investor sentiment and higher price targets. Upward analyst revisions tend to lift momentum in the shares. Research Analysts Offer Predictions for HALO FY2025 Earnings
• Positive Sentiment: Recent quarterly results (Nov. 3) showed an EPS and revenue beat and strong margins/ROE, reinforcing the thesis that ENHANZE-driven royalties and commercial growth can sustain higher profitability. That fundamental strength underpins current multiple expansion. MarketBeat Halozyme summary and earnings recap
• Neutral Sentiment: Longer-term thematic coverage notes medtech companies seeing multi‑decade growth opportunities; if Halozyme is included in that narrative it could support longer-duration investor interest but is more thematic than immediately catalytic. This medical technology leader sees growth into the 2040s
• Neutral Sentiment: Institutional ownership remains very high (~98%) and analyst ratings are mixed (buys, holds, one sell). That concentration can amplify moves but also limits free float liquidity. MarketBeat institutional & analyst snapshot
• Negative Sentiment: CEO Helen Torley has sold multiple blocks of shares recently (10,000 shares on Feb 5 at ~$78.64; prior sales of 20,000 at ~$76.12 and other sales in 2025/2024). Insider selling can create short‑term pressure or raise governance questions for some investors. Insider Selling: Halozyme Therapeutics CEO Sells 10,000 Shares

Insider Activity

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the sale, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. This represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction on Monday, November 10th. The stock was sold at an average price of $68.48, for a total value of $136,960.00. Following the sale, the director owned 42,952 shares in the company, valued at $2,941,352.96. This trade represents a 4.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 71,398 shares of company stock worth $5,170,152. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.